Assessing antibiotic resistance in Helicobacter pylori in Korea
Prevalence and Trends of Antimicrobial Resistance of Helicobacter Pylori in Korea
This study looks at how common antibiotic resistance is in Helicobacter pylori bacteria from patients with stomach issues in Korea to help improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Seoul National University Bundang Hospital Academic / other |
| Locations | 1 site (Seongnam-si, Gyeonggi-do) |
| Trial ID | NCT05247112 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the prevalence and trends of antimicrobial resistance in Helicobacter pylori isolated from patients with upper gastrointestinal diseases over a long-term period. By analyzing H. pylori cultures collected since 2003, the study will investigate minimal inhibitory concentrations and resistance rates to various antibiotics. It will also explore risk factors associated with antibiotic resistance and the implications for treatment failure. The findings are expected to inform future eradication strategies for H. pylori infections.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with Helicobacter pylori infection who consent to undergo culture analysis via endoscopic resection.
Not a fit: Patients with concurrent critical illnesses, those who have recently taken antibiotics or certain medications, and pregnant or nursing individuals may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for Helicobacter pylori infections, enhancing eradication rates and patient outcomes.
How similar studies have performed: While there may be studies on antimicrobial resistance in H. pylori, this specific long-term trend analysis appears to be novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects who had a H. pylori infection and had consented to undergo culture analysis via endoscopic resection, in order to determine the minimal inhibitory concentration (MIC) of various antibiotics. Exclusion Criteria: * Patients with a concurrent critical illness, who abused drugs or alcohol, who were pregnant or nursing, or those who had received antibiotics, PPIs, or bismuth salts within 4 weeks, were excluded.
Where this trial is running
Seongnam-si, Gyeonggi-do
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, South Korea (Recruiting)
Study contacts
- Study coordinator: Jung Won Lee, M.D.
- Email: saludos@naver.com
- Phone: + 82-10-9356-7758
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.